**Supplementary Table 1** Clinical characteristics of studies included in the network meta-analysis.

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Author, year** | **Eligibility, stage** | **Study type** | **Total****no.** | **Treatment strategy** | **Time point of response evaluation** | **Regimen****classifier** | **Chemotherapy****Regimen (no.)** | **Tumor response rate (%)** | **PFS %****(y)** | **OS %****(y)** |
| **CR** | **ORR** |
| Wang 2015 39 | Newly,Stage I-II | Retrospective | 93 | CT+RT | Induction | ASP/GEM-based | GELOX (40) | 28 (70.0) | 35 (87.5) | 79.0 (5) | 78.9 (5) |
| ANT-based | EPOCH (53) | 22 (41.5) | 36 (67.9) | 46.5 (5) | 50.4 (5) |
| Bu 2016 38 | Stage I-IVI-II (153)III-IV (28) | Retrospective | 181 | CT+RT | After the induction CT | ASP/NOS-based | L-CHOP, LVP, COP-L, L-ASP (112) | 38 | 76 (67.9) | 50 （5） | 65.1 (5) |
| ANT-based | CHOP (69) | 10 | 32 (46.4) | 21 （5） | 28.4（5） |
| Qi 2016 37 | Newly,Stage I-IVI-II (20)III-IV (10) | Retrospective | 30 | CT±RT | After the initial CT | ASP/MTX-based | m-SMILE (20) | 16 (80.0) | 19 (95.0) |  | 73.1(5)\* |
| ANT-based | Accelerated CHOP (10) | 3 (30.0) | 9 (90.0) |  | 58.3(5)\* |
| Zhou 2016 36 | Newly,Stage I-II | Prospective (Phase II) | 64 | CT+RT | After the induction CT | ASP/GEM-based | SMILE (34) | 18 (52.9) | 30 (88.2) | 64(3) | 66 (3) |
| ANT-based | CHOP (30) | 10 (33.3) | 15 (50.0) | 51(3) | 53 (3) |
| Huang 201735 | Newly,Stage II | Retrospective | 80 | CT+RT | After the induction CT | ASP/NOS-based | LOP (48) | 31 （64.6） | 42 (87.5) | 79.2 (3) | 87.5 (3) |
| ANT-based | CHOP (32) | 14 (43.8) | 18 (56.3) | 50 (3) | 62.5 (3) |
| Wei 2020 34 | Newly,Stage I-IV | Prospective | 103 | CT±RT | After the induction/initial CT | ASP/GEM-based | P-GEMOX (51) | 15 (29.4) | 45 (88.2) | 83.9 (3) | 88.2 (3) |
| ASP/NOS-based | SVILE (52) | 15 (28.8) | 45 (86.5) | 75.4 (3) | 82.6 (3) |
|  | I-II (69) |  |  |  | After the induction CT | ASP/GEM-based | P-GEMOX (33) | 13 (39.4) | 32 (97.0) | 93.9 (3) | 97.0 (3) |
| ASP/NOS-based | SVILE (36) | 14 (38.9) | 33 (91.7) | 88.3 (3) | 88.8 (3) |
|  | III-IV (34) |  |  |  | After the initial CT | ASP/GEM-based | P-GEMOX (18) | 2 (11.1) | 13 (72.2) | 65.7 (3) | 72.2 (3) |
| ASP/NOS-based | SVILE (16) | 1 (6.2) | 12 (75.0) | 46.2 (3) | 68.8 (3) |
| Li 2021 9 | Newly,Stage III-IV | Retrospective,multicenter | 66 | CT | After the initial CT | ASP/GEM-based | GELOXD (44) |  |  | 47.7 (3) | 55.4 (3) |
| ASP/MTX-based | m-SMILE (22) |  |  | 51.4 (3) | 45.9 (3) |
| Zheng 2021 33 | Newly,Stage I-II | Retrospective | 376 | CT±RT |  | ASP/GEM-based | ASP/GEM/PLA (286) |  |  |  | 84.5 (5) |
| Non-ASP/ANT-based | GEM/PLA (90) |  |  |  | 73.2 (5) |
| Wang 2022 18 | Newly,Stage III-IV | Prospective | 80 | CT | After the initial CT | ASP/GEM-based | DDGP (40) | 27 (67.5) | 36 (90.0) | 56.6 (3) | 74.3 (5) |
| ASP/MTX-based | SMILE (40) | 19 (47.5) | 24 (60.0) | 41.8 (3) | 51.7 (5) |
| Zhang 2022 32 | Newly,Stage I-II | Retrospective | 40 | CT+RT | After the initial CT and RT | ASP/GEM-based | DDGP (20) | 17 (85.0) | 19 (95.0) | 83.3 (5) | 83.0 (5) |
| Non-ANT/ASP-based | VIPD (20) | 10 (50.0) | 13 (65.0) | 44.4 (5) | 72.1 (5) |

\*Estimated from the figures.